Online citations, reference lists, and bibliographies.
Referencing for people who value simplicity, privacy, and speed.
Get Citationsy
← Back to Search

Tumor Metastases And Cell‐mediated Immunity In A Model System In DBA/2 Mice. VI. Similar Specificity Patterns Of Protective Anti‐tumor Immunity In Vivo And Of Cytolytic T Cells In Vitro

K. Bosslet, V. Schirrmacher, G. Shantz
Published 1979 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
In an attempt to analyze mechanisms of immunity against tumor metastases, protective anti‐tumor immunity in vivo was compared with cytotoxic T‐cell activity in vitro in a well‐defined syngeneic tumor model system. The system consists of a chemically induced parental tumor cell line (Eb) with little or no metastatic potential and a spontaneous variant thereof (ESb) with pronounced metastatic properties. Tumor protection experiments revealed the presence of tumor‐associated transplantation antigens (TATAs) on both Eb and ESb tumor cells. TATAs of Eb and ESb were found to be distinct and non‐cross‐reactive. One of several unrelated tumors, however, RL♂1, expressed TATAs which cross‐reacted with those of Eb. Protective immunity against the non‐metastasizing tumor was much stronger than that against the metastasizing variant. Furthermore, the optimal procedures for induction of immunity in vivo were strikingly different for each tumor. Tumor‐specific cytotoxic T lymphocytes (CTLs) were obtained after sensitization in vivo with viable tumor cells and restimulation in vitro for 4–5 days with mitomycin‐C‐treated autologous tumor cells. Both anti‐Eb and anti‐ESb CTLs showed high cytolytic activity in a 4‐h 51Cr release assay against the autologous tumor lines. The target antigens recognized by these cells were similar to the TATAs as defined in the protection experiments. (1) The target antigens of Eb and ESb were distinct and non‐cross‐reactive. (2) Only one of 14 unrelated syngeneic and allogeneic tumors expressed a target antigen which cross‐reacted with that of Eb. (3) This tumor was the radiation‐induced BALB/c lymphoma RL♂1 which also cross‐reacted at the level of the TATAs. The correlations between protective immunity obtained in vivo and cytolytic T cells induced in vitro suggest that cytolytic T cells can recognize TATAs and may thus play an important role in the establishment of protective immunity.
This paper references
Studies of H-2 restriction in cell-mediated cytotoxicity and transplantation immunity to Leukemia-associated antigens.
C. Ting (1977)
10.1002/IJC.2910230216
Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice.: Iv. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes
V. Schirrmacher (1979)
10.1002/IJC.2910240114
Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice. V. Transfer of protective immunity with H‐2 identical immune T cells from B10.D2 mice
V. Schirrmacher (1979)
Regional differences in the incidence and growth of mouse tumors following intradermal or subcutaneous inoculation.
R. Auerbach (1978)
10.1002/1097-0142(197707)40:1+<467::AID-CNCR2820400709>3.0.CO;2-6
Back to the drawing board—the need for more realistic model systems for immunotherapy
P. Alexander (1977)
10.1093/JNCI/56.6.1211
Secondary cell-mediated cytotoxic response to challenge of rats with syngeneic Gross virus-induced lymphoma.
M. Glaser (1976)
10.1016/0008-8749(76)90331-2
Murine thymic lymphomas as model tumors for T-cell studies. T-cell markers, immunoglobulin and Fc-receptors on AKR thymomas.
P. Krammer (1976)
10.1002/IJC.2910160609
Secondary specific immune response in vitro to MSV tumor cells
A. Senik (1975)
10.1002/IJC.2910200108
Antigenic differences between primary methylcholanthrene‐induced rat sarcomas and post‐surgical recurrences
M. V. Pimm (1977)
10.1002/EJI.1830050402
Primary and secondary in vitro generation of cytolytic T lymphocytes in the murine sarcoma virus system
F. Plata (1975)
10.1016/S0340-904X(79)80014-7
75Se-release: a short and long term assay system for cellular cytoxicity.
W. Leibold (1979)
10.1007/978-1-4615-9101-6_126
Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. 2. Characteristics of a metastasizing variant of a chemically induced lymphoma.
V. Schirrmacher (1979)
10.1002/IJC.2910230215
Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastasis formation in vivo
V. Schirrmacher (1979)
10.1093/JNCI/53.4.1103
Specificity of 5lCr-Release Cytotoxicity of Lymphocytes Immune to Murine Sarcoma Virus
R. Herberman (1974)
10.1093/JNCI/18.6.769
Immunity to methylcholanthrene-induced sarcomas.
R. Prehn (1957)
10.1038/bjc.1972.24
Response of Syngeneic Murine Lymphomata to Immunotherapy in Relation to the Antigencity of the Tumour
I. Parr (1972)
Characterization of a rapidly growing AKR lymphoblastic cell line maintaining Gross antigens and viral replication.
W. Woods (1970)
10.1093/JNCI/50.2.347
Progressive loss of H-2 antigens with concomitant increase of cell-surface antigen(s) determined by Moloney leukemia virus in cultured murine lymphomas.
M. Čikeš (1973)
10.1002/IJC.2910140114
Transplantation immunity to individually unique antigens of chemically induced bladder tumors in mice
D. Wahl (1974)
In vivo protection against syngeneic Gross virus-induced lymphoma in rats: comparison with in vitro studies of cell-mediated immunity.
M. Glaser (1976)
10.1002/IJC.2910100318
Cell‐mediated reaction against tumors induced by oncornaviruses. I. Kinetics and specificity of the immune response in Murine sarcoma virus (MSV)‐induced tumors and transplanted lymphomas
J. C. Leclerc (1972)
10.1097/00007890-197207000-00014
DEVELOPMENT OF A NEW SKIN ANTIGEN AND OF TOLERANCE TO THIS ANTIGEN IN MICE INFECTED WITH A LYMPHOMAGENIC VIRUS
M. Salaman (1972)
Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells.
J. Berenson (1975)
10.1002/IJC.2910220513
Induction of a tumor with greatly increased metastatic growth potential by injection of cells from a low‐metastatic H‐2 heterozygous tumor cell line into an H‐2 incompatible parental strain
R. Kerbel (1978)
10.1084/JEM.138.3.593
LEUKEMIA-ASSOCIATED TRANSPLANTATION ANTIGENS RELATED TO MURINE LEUKEMIA VIRUS
H. Sato (1973)
Cell-mediated immunity to friend virus-induced leukemia. IV. In vitro generation of primary and secondary cell-mediated cytotoxic responses.
C. Ting (1976)
Characterization and specificity of murine anti-tumor cytotoxic effector cells within an ascitic tumor.
W. Biddison (1977)
10.1097/00007890-196807000-00053
TUMOR-SPECIFIC ANTIGENS OF METHYLCHOLANTHRENE-INDUCED SARCOMAS: IN VITRO STUDIES
C. Mckhann (1968)
10.1093/JNCI/64.6.1413
Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. VII. Interaction of metastasizing and nonmetastasizing tumors with normal tissue in vitro.
M. Lohmann‐Matthes (1980)
Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host.
G. Klein (1960)
Xenogeneic recognition of tumour spcific plasma membrane antigens derived from mouse lymphoma cells.
A. Wolf (1972)
In vitro demonstration of altered antigenicity of metastases from a primary methylcholanthrene-induced sarcoma.
Faraci Rp (1974)
10.1126/science.176.4041.1337
Immunological Studies on Urinary Bladder Tumors of Rats and Mice
L. A. Taranger (1972)
10.1002/JSS.400110111
Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. VIII. Expression and shedding of Fc gamma receptors on metastatic tumor cell variants.
V. Schirrmacher (1979)
Secondary cell-mediated cytotoxic response to syngeneic mouse tumor challenge.
H. T. Holden (1975)
In vitro induction of tumor specific immunity. VII. Does autosensitization occur with in vitro culture of T lymphocytes?
R. Burton (1977)
10.1038/bjc.1975.30
Photodynamic destruction of human bladder carcinoma.
J. Kelly (1975)
10.1038/bjc.1976.2
Spontaneous shedding and antibody induced modulation of histocompatibility antigens on murine lymphomata: Correlation with metastic capacity.
G. Davey (1976)



This paper is referenced by
10.1007/978-1-4899-5037-6_11
Postoperative activation of tumor specific T cells by immunization with virus-modified tumor cells and effects on metastasis.
V. Schirrmacher (1988)
10.1002/EJI.1830120409
Different expression of Lyt differentiation antigens and cell surface glycoproteins by a murine T lymphoma line and its highly metastatic variant
P. Altevogt (1982)
10.1007/BF00200203
Clonal analysis of expression of tumor-associated transplantation antigens and of metastatic capacity
V. Schirrmacher (2004)
10.1007/978-3-642-73642-1_12
Successful Application of a Virus-Modified Tumor Vaccine for Anti-Metastatic Cancer Immunotherapy
V. Schirrmacher (1989)
Characterization of L5178Y cell phenotypes isolated during progression of the tumor-dormant state in DBA2 mice.
Trainer Dl (1984)
10.1002/IJC.2910430225
Recruitment and activation of tumor‐specific immune t cells in situ: Functional studies using a sponge matrix model
U. Zangemeister (1989)
Loss of endogenous mouse mammary tumor virus superantigen increases tumor resistance.
V. Schirrmacher (1998)
10.1016/0304-419X(82)90020-8
Cancer metastasis. Organ colonization and the cell-surface properties of malignant cells.
G. Nicolson (1982)
10.1007/978-1-4615-0081-0
New Trends in Cancer for the 21st Century
M. Hildebrandt (2003)
10.1038/bjc.1981.192
A rapid method for the isolation of metastasizing tumour cells from internal organs with the help of isopycnic density-gradient centrifugation in Percoll.
K. Bosslet (1981)
10.1111/J.1749-6632.1988.TB36378.X
Activation of Tumor‐Specific CTLP to a Cytolytic Stage Requires Additional Signals
P. Hoegen (1988)
10.1007/BF00124215
Intratumor immunologic heterogeneity
F. R. Miller (2004)
10.1084/JEM.160.5.1579
Acquisition of high metastatic capacity after in vitro fusion of a nonmetastatic tumor line with a bone marrow-derived macrophage
L. Larizza (1984)
10.1155/1998/93545
Differential Activation of CD8+ Tumor-Specific Tc1 and Tc2 Cells by an IL-10-Producing Murine Plasmacytoma
C. Specht (1998)
10.1006/SCBI.2001.0384
T-cell immunity in the induction and maintenance of a tumour dormant state.
V. Schirrmacher (2001)
10.1007/978-3-642-74236-1_20
Active Specific Immunotherapy with Autologous Tumor Cell Vaccines Modified by Newcastle Disease Virus: Experimental and Clinical Studies
V. Schirrmacher (1989)
10.1016/S0171-2985(80)80091-X
Shifts in tumor cell phenotypes induced by signals from the microenvironment. Relevance for the immunobiology of cancer metastasis.
V. Schirrmacher (1980)
10.1007/978-1-4615-0081-0_14
Improvements of survival in nine phase II clinical studies with different types of cancer upon anti-tumor vaccination with an autologous tumor cell vaccine modified by virus infection to introduce danger signals.
Volker Schirrmaker (2003)
10.1007/BF00205796
Modification of tumor cells by a low dose of Newcastle disease virus
H. Schild (2004)
Brief Det~nitive Report Hepatocyte-tumor Cell Interaction in Vitro I. Conditions for Rosette Formation and Inhibition By
Anti-H Antibody ()
10.1002/IJC.2910230215
Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastasis formation in vivo
V. Schirrmacher (1979)
Phenotypic Shifts in the L 5178 Y Lymphoma Population during Progression of the Tumor-dormant State in DBA / 2 Mice 1
D. L. Trainer (2006)
10.1007/978-3-642-69290-1
Hormonally Defined Media
G. Fischer (1983)
A novel model system for the study of anti-tumour T-cell memory
Y. Mahnke (2001)
10.1016/0008-8749(87)90317-0
New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor-specific cytolytic T cells.
P. von Hoegen (1987)
10.1007/BF01741332
Specific eradication of micrometastases by transfer of tumour-immune T cells from major-histocompatibility-complex congenic mice
V. Schirrmacher (2005)
10.1038/sj.gt.3300787
Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus
V. Schirrmacher (1999)
10.1002/IJC.2910250614
Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice X. Immunoselection of tumor variants differing in tumor antigen expression and metastatic capacity
V. Schirrmacher (1980)
10.1002/IJC.2910290214
High‐frequency generation of new immunoresistant tumor variants during metastasis of a cloned murine tumor line (ESb)
K. Bosslet (1982)
10.1016/S0171-2985(86)80068-7
Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. IV. Tumor-specific T suppressor cells, induced at early stages of tumorigenesis, act on the induction phase of the tumor-specific cytotoxic T cell response.
H. Haubeck (1986)
10.1007/BF01741168
Induction of cell-mediated immunity against B16-BL6 melanoma in mice vaccinated with cells modified by hydrostatic pressure and chemical crosslinking
A. Eisenthal (2005)
10.1084/JEM.154.2.557
Escape of metastasizing clonal tumor cell variants from tumor-specific cytolytic T lymphocytes
K. Bosslet (1981)
See more
Semantic Scholar Logo Some data provided by SemanticScholar